Stem definition | Drug id | CAS RN |
---|---|---|
1745 | 60-56-0 |
Dose | Unit | Route |
---|---|---|
10 | mg | O |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 8.76 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
BA (Bioavailability) | 93 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.86 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 21, 1950 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Agranulocytosis | 324.90 | 14.11 | 124 | 8000 | 21297 | 50575703 |
Thyrotoxic crisis | 221.69 | 14.11 | 45 | 8079 | 707 | 50596293 |
Hyperthyroidism | 200.83 | 14.11 | 75 | 8049 | 12100 | 50584900 |
Antithyroid arthritis syndrome | 66.33 | 14.11 | 9 | 8115 | 4 | 50596996 |
Hypothyroidism | 66.16 | 14.11 | 50 | 8074 | 34075 | 50562925 |
Choanal atresia | 59.11 | 14.11 | 9 | 8115 | 20 | 50596980 |
Exophthalmos | 45.64 | 14.11 | 14 | 8110 | 1236 | 50595764 |
Blood thyroid stimulating hormone decreased | 35.46 | 14.11 | 16 | 8108 | 4156 | 50592844 |
Drug-induced liver injury | 35.26 | 14.11 | 32 | 8092 | 28063 | 50568937 |
Neutropenia | 34.00 | 14.11 | 74 | 8050 | 147891 | 50449109 |
Dysmorphism | 30.85 | 14.11 | 12 | 8112 | 2155 | 50594845 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 30.04 | 14.11 | 12 | 8112 | 2310 | 50594690 |
Goitre | 28.85 | 14.11 | 15 | 8109 | 5305 | 50591695 |
Pulmonary alveolar haemorrhage | 26.67 | 14.11 | 13 | 8111 | 4014 | 50592986 |
Cardiac arrest | 26.64 | 14.11 | 48 | 8076 | 83603 | 50513397 |
Mucocutaneous candidiasis | 26.56 | 14.11 | 4 | 8120 | 8 | 50596992 |
Endocrine ophthalmopathy | 26.39 | 14.11 | 7 | 8117 | 366 | 50596634 |
Polyarthritis | 25.79 | 14.11 | 16 | 8108 | 7911 | 50589089 |
Oropharyngeal pain | 25.23 | 14.11 | 45 | 8079 | 77756 | 50519244 |
Aplasia cutis congenita | 25.23 | 14.11 | 5 | 8119 | 69 | 50596931 |
Neuroglycopenia | 25.23 | 14.11 | 5 | 8119 | 69 | 50596931 |
Thyroxine free increased | 25.18 | 14.11 | 8 | 8116 | 793 | 50596207 |
Drug intolerance | 24.85 | 14.11 | 3 | 8121 | 219101 | 50377899 |
Toxic nodular goitre | 24.51 | 14.11 | 4 | 8120 | 16 | 50596984 |
Drug interaction | 22.67 | 14.11 | 77 | 8047 | 199544 | 50397456 |
Eosinophilic pleural effusion | 20.85 | 14.11 | 4 | 8120 | 46 | 50596954 |
Thyroid haemorrhage | 20.19 | 14.11 | 4 | 8120 | 55 | 50596945 |
Acquired epidermolysis bullosa | 20.13 | 14.11 | 4 | 8120 | 56 | 50596944 |
Toxic goitre | 19.92 | 14.11 | 3 | 8121 | 6 | 50596994 |
Sopor | 19.92 | 14.11 | 20 | 8104 | 19859 | 50577141 |
Thyroidectomy | 19.70 | 14.11 | 7 | 8117 | 977 | 50596023 |
Electrocardiogram QT prolonged | 19.43 | 14.11 | 32 | 8092 | 51854 | 50545146 |
Autoimmune neutropenia | 19.29 | 14.11 | 4 | 8120 | 70 | 50596930 |
Functional residual capacity increased | 19.13 | 14.11 | 4 | 8120 | 73 | 50596927 |
Insulin autoimmune syndrome | 19.08 | 14.11 | 4 | 8120 | 74 | 50596926 |
Thyroid disorder | 19.04 | 14.11 | 16 | 8108 | 12661 | 50584339 |
Hypoglycaemia | 18.68 | 14.11 | 32 | 8092 | 53549 | 50543451 |
Stevens-Johnson syndrome | 18.41 | 14.11 | 20 | 8104 | 21732 | 50575268 |
Respiratory syncytial virus infection | 18.40 | 14.11 | 11 | 8113 | 5091 | 50591909 |
Jaundice cholestatic | 18.38 | 14.11 | 11 | 8113 | 5100 | 50591900 |
Symptom masked | 18.25 | 14.11 | 6 | 8118 | 663 | 50596337 |
Hypersensitivity vasculitis | 18.07 | 14.11 | 10 | 8114 | 4005 | 50592995 |
Clinodactyly | 18.05 | 14.11 | 4 | 8120 | 97 | 50596903 |
Thyroxine free abnormal | 16.86 | 14.11 | 3 | 8121 | 22 | 50596978 |
Rheumatoid arthritis | 16.42 | 14.11 | 6 | 8118 | 202544 | 50394456 |
Cardiac failure | 16.27 | 14.11 | 37 | 8087 | 76003 | 50520997 |
Metabolic function test abnormal | 16.05 | 14.11 | 4 | 8120 | 163 | 50596837 |
Microscopic polyangiitis | 16.00 | 14.11 | 4 | 8120 | 165 | 50596835 |
Atrial fibrillation | 15.98 | 14.11 | 44 | 8080 | 101701 | 50495299 |
Arthropathy | 15.98 | 14.11 | 3 | 8121 | 157903 | 50439097 |
Spigelian hernia | 15.60 | 14.11 | 3 | 8121 | 35 | 50596965 |
Kidney transplant rejection | 15.44 | 14.11 | 9 | 8115 | 3978 | 50593022 |
Febrile neutropenia | 15.11 | 14.11 | 42 | 8082 | 97625 | 50499375 |
Acute generalised exanthematous pustulosis | 14.93 | 14.11 | 12 | 8112 | 8926 | 50588074 |
Mucosal erosion | 14.42 | 14.11 | 6 | 8118 | 1281 | 50595719 |
Hepatitis cholestatic | 14.19 | 14.11 | 10 | 8114 | 6107 | 50590893 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hyperthyroidism | 160.00 | 19.42 | 54 | 3568 | 8554 | 29562351 |
Agranulocytosis | 76.53 | 19.42 | 41 | 3581 | 20299 | 29550606 |
Thyrotoxic periodic paralysis | 66.56 | 19.42 | 11 | 3611 | 67 | 29570838 |
Hypothyroidism | 54.09 | 19.42 | 30 | 3592 | 15876 | 29555029 |
Thyrotoxic crisis | 49.81 | 19.42 | 11 | 3611 | 348 | 29570557 |
Kounis syndrome | 48.32 | 19.42 | 15 | 3607 | 1814 | 29569091 |
Polymerase chain reaction | 43.64 | 19.42 | 8 | 3614 | 95 | 29570810 |
Exomphalos | 33.96 | 19.42 | 7 | 3615 | 158 | 29570747 |
Albumin urine present | 33.38 | 19.42 | 8 | 3614 | 365 | 29570540 |
Cholestatic liver injury | 32.88 | 19.42 | 11 | 3611 | 1686 | 29569219 |
Urine leukocyte esterase positive | 32.72 | 19.42 | 8 | 3614 | 397 | 29570508 |
Goitre | 30.39 | 19.42 | 10 | 3612 | 1457 | 29569448 |
Haemoglobinuria | 29.75 | 19.42 | 8 | 3614 | 581 | 29570324 |
Mouth swelling | 29.68 | 19.42 | 10 | 3612 | 1566 | 29569339 |
Pericarditis fungal | 28.37 | 19.42 | 6 | 3616 | 154 | 29570751 |
Respiratory tract haemorrhage | 25.86 | 19.42 | 8 | 3614 | 956 | 29569949 |
Autoimmune thyroiditis | 25.29 | 19.42 | 8 | 3614 | 1028 | 29569877 |
Urine ketone body present | 25.20 | 19.42 | 8 | 3614 | 1040 | 29569865 |
Axial spondyloarthritis | 25.13 | 19.42 | 6 | 3616 | 269 | 29570636 |
Glycosuria | 24.38 | 19.42 | 8 | 3614 | 1154 | 29569751 |
Loss of proprioception | 23.30 | 19.42 | 6 | 3616 | 368 | 29570537 |
Tracheo-oesophageal fistula | 22.47 | 19.42 | 6 | 3616 | 424 | 29570481 |
Blood cyanide increased | 22.10 | 19.42 | 4 | 3618 | 44 | 29570861 |
Coagulation time shortened | 21.17 | 19.42 | 5 | 3617 | 214 | 29570691 |
Blood sodium decreased | 20.72 | 19.42 | 16 | 3606 | 14751 | 29556154 |
Electrolyte imbalance | 19.83 | 19.42 | 14 | 3608 | 11260 | 29559645 |
Urinary bladder rupture | 19.59 | 19.42 | 4 | 3618 | 86 | 29570819 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Agranulocytosis | 357.87 | 13.38 | 158 | 10513 | 38071 | 64449990 |
Hyperthyroidism | 282.27 | 13.38 | 108 | 10563 | 18071 | 64469990 |
Thyrotoxic crisis | 252.95 | 13.38 | 54 | 10617 | 1062 | 64486999 |
Hypothyroidism | 103.56 | 13.38 | 71 | 10600 | 40386 | 64447675 |
Antithyroid arthritis syndrome | 66.06 | 13.38 | 9 | 10662 | 4 | 64488057 |
Thyrotoxic periodic paralysis | 60.41 | 13.38 | 11 | 10660 | 90 | 64487971 |
Exophthalmos | 50.30 | 13.38 | 16 | 10655 | 1544 | 64486517 |
Drug-induced liver injury | 46.67 | 13.38 | 48 | 10623 | 47595 | 64440466 |
Goitre | 44.66 | 13.38 | 20 | 10651 | 4953 | 64483108 |
Anti-neutrophil cytoplasmic antibody positive vasculitis | 43.94 | 13.38 | 17 | 10654 | 2919 | 64485142 |
Polymerase chain reaction | 39.31 | 13.38 | 8 | 10663 | 123 | 64487938 |
Kounis syndrome | 36.51 | 13.38 | 15 | 10656 | 3010 | 64485051 |
Endocrine ophthalmopathy | 30.06 | 13.38 | 8 | 10663 | 411 | 64487650 |
Polyarthritis | 27.11 | 13.38 | 18 | 10653 | 9697 | 64478364 |
Albumin urine present | 26.45 | 13.38 | 8 | 10663 | 653 | 64487408 |
Pericarditis fungal | 25.97 | 13.38 | 6 | 10665 | 171 | 64487890 |
Blood thyroid stimulating hormone decreased | 25.85 | 13.38 | 14 | 10657 | 5216 | 64482845 |
Haemoglobinuria | 25.64 | 13.38 | 8 | 10663 | 725 | 64487336 |
Cardiac failure | 25.55 | 13.38 | 63 | 10608 | 132310 | 64355751 |
Autoimmune thyroiditis | 24.87 | 13.38 | 12 | 10659 | 3516 | 64484545 |
Neuroglycopenia | 24.69 | 13.38 | 5 | 10666 | 75 | 64487986 |
Neutropenia | 24.38 | 13.38 | 91 | 10580 | 239533 | 64248528 |
Toxic goitre | 24.20 | 13.38 | 4 | 10667 | 17 | 64488044 |
Jaundice cholestatic | 24.03 | 13.38 | 16 | 10655 | 8654 | 64479407 |
Cardiac arrest | 23.32 | 13.38 | 67 | 10604 | 153997 | 64334064 |
Thyroxine free increased | 22.40 | 13.38 | 8 | 10663 | 1099 | 64486962 |
Drug interaction | 22.06 | 13.38 | 118 | 10553 | 361965 | 64126096 |
Cholestatic liver injury | 21.45 | 13.38 | 11 | 10660 | 3668 | 64484393 |
Mucocutaneous candidiasis | 21.24 | 13.38 | 4 | 10667 | 40 | 64488021 |
Electrocardiogram QT prolonged | 21.15 | 13.38 | 43 | 10628 | 79405 | 64408656 |
Drug intolerance | 21.12 | 13.38 | 3 | 10668 | 187989 | 64300072 |
Blood cyanide increased | 20.90 | 13.38 | 4 | 10667 | 44 | 64488017 |
Atrial fibrillation | 20.87 | 13.38 | 69 | 10602 | 171020 | 64317041 |
Respiratory tract haemorrhage | 20.12 | 13.38 | 8 | 10663 | 1476 | 64486585 |
Urine leukocyte esterase positive | 19.34 | 13.38 | 10 | 10661 | 3393 | 64484668 |
Hepatitis cholestatic | 19.20 | 13.38 | 16 | 10655 | 12139 | 64475922 |
Sopor | 19.02 | 13.38 | 24 | 10647 | 29637 | 64458424 |
Oropharyngeal pain | 18.97 | 13.38 | 44 | 10627 | 88823 | 64399238 |
Functional residual capacity increased | 18.81 | 13.38 | 4 | 10667 | 77 | 64487984 |
Thyroid haemorrhage | 18.71 | 13.38 | 4 | 10667 | 79 | 64487982 |
Completed suicide | 18.49 | 13.38 | 7 | 10664 | 224407 | 64263654 |
Acquired epidermolysis bullosa | 18.39 | 13.38 | 4 | 10667 | 86 | 64487975 |
Urinary bladder rupture | 18.05 | 13.38 | 4 | 10667 | 94 | 64487967 |
Pulmonary alveolar haemorrhage | 17.89 | 13.38 | 14 | 10657 | 9724 | 64478337 |
Glycosuria | 17.54 | 13.38 | 8 | 10663 | 2066 | 64485995 |
Thyroidectomy | 16.92 | 13.38 | 6 | 10665 | 807 | 64487254 |
Coagulation time shortened | 16.87 | 13.38 | 5 | 10666 | 381 | 64487680 |
Jaundice | 16.30 | 13.38 | 29 | 10642 | 48483 | 64439578 |
Thyroid dermatopathy | 16.22 | 13.38 | 3 | 10668 | 27 | 64488034 |
Immune-mediated hepatitis | 16.15 | 13.38 | 8 | 10663 | 2481 | 64485580 |
Ventricular septal defect | 15.91 | 13.38 | 5 | 10666 | 464 | 64487597 |
Mouth swelling | 15.56 | 13.38 | 10 | 10661 | 5097 | 64482964 |
Metabolic function test abnormal | 15.52 | 13.38 | 4 | 10667 | 181 | 64487880 |
Tri-iodothyronine increased | 15.44 | 13.38 | 4 | 10667 | 185 | 64487876 |
Antineutrophil cytoplasmic antibody | 15.43 | 13.38 | 3 | 10668 | 36 | 64488025 |
Hypersensitivity vasculitis | 15.27 | 13.38 | 11 | 10660 | 6750 | 64481311 |
Toxic nodular goitre | 15.21 | 13.38 | 3 | 10668 | 39 | 64488022 |
Bradycardia | 14.69 | 13.38 | 48 | 10623 | 118171 | 64369890 |
Symptom masked | 14.63 | 13.38 | 6 | 10665 | 1198 | 64486863 |
Respiratory syncytial virus infection | 14.56 | 13.38 | 11 | 10660 | 7257 | 64480804 |
Tonsillitis | 14.37 | 13.38 | 10 | 10661 | 5810 | 64482251 |
Cholestasis | 14.03 | 13.38 | 26 | 10645 | 44846 | 64443215 |
Urine ketone body present | 14.01 | 13.38 | 8 | 10663 | 3299 | 64484762 |
Eosinophilic pleural effusion | 13.98 | 13.38 | 4 | 10667 | 269 | 64487792 |
Pure white cell aplasia | 13.77 | 13.38 | 3 | 10668 | 65 | 64487996 |
Hepatitis | 13.74 | 13.38 | 26 | 10645 | 45556 | 64442505 |
Hypoglycaemia | 13.50 | 13.38 | 39 | 10632 | 89853 | 64398208 |
Oedema mucosal | 13.44 | 13.38 | 6 | 10665 | 1473 | 64486588 |
None
Source | Code | Description |
---|---|---|
ATC | H03BB02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY ANTITHYROID PREPARATIONS Sulfur-containing imidazole derivatives |
ATC | H03BB52 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS THYROID THERAPY ANTITHYROID PREPARATIONS Sulfur-containing imidazole derivatives |
MeSH PA | D013956 | Antithyroid Agents |
MeSH PA | D006727 | Hormone Antagonists |
FDA MoA | N0000175917 | Thyroid Hormone Synthesis Inhibitors |
FDA EPC | N0000175918 | Thyroid Hormone Synthesis Inhibitor |
CHEBI has role | CHEBI:50671 | antithyroid drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hyperthyroidism | indication | 34486009 | DOID:7998 |
Thyrotoxic crisis | off-label use | 29028009 | DOID:12837 |
Agranulocytosis | contraindication | 17182001 | DOID:12987 |
Hypothyroidism | contraindication | 40930008 | DOID:1459 |
Factor II deficiency | contraindication | 73975000 | |
Leukopenia | contraindication | 84828003 | DOID:615 |
Pancytopenia | contraindication | 127034005 | DOID:12450 |
Liver function tests abnormal | contraindication | 166603001 | |
Drug-induced hepatitis | contraindication | 235876009 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Bone marrow depression | contraindication | 307762000 |
None
Product | Applicant | Ingredients |
---|---|---|
Felimazole | Dechra, Ltd. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.7 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Thyroid peroxidase | Enzyme | INHIBITOR | IC50 | 5.57 | WOMBAT-PK | CHEMBL | |||
Lactoperoxidase | Enzyme | IC50 | 4.93 | CHEMBL | |||||
Lactoperoxidase | Enzyme | IC50 | 5.08 | CHEMBL | |||||
Dopamine beta-hydroxylase | Enzyme | Ki | 4.35 | CHEMBL |
ID | Source |
---|---|
4017434 | VUID |
N0000145822 | NUI |
D00401 | KEGG_DRUG |
4017434 | VANDF |
C0025644 | UMLSCUI |
CHEBI:50673 | CHEBI |
MMZ | PDB_CHEM_ID |
CHEMBL1515 | ChEMBL_ID |
DB00763 | DRUGBANK_ID |
6649 | IUPHAR_LIGAND_ID |
554Z48XN5E | UNII |
1349907 | PUBCHEM_CID |
224936 | RXNORM |
2293 | MMSL |
31962 | MMSL |
5073 | MMSL |
d00290 | MMSL |
002139 | NDDF |
37656002 | SNOMEDCT_US |
404864000 | SNOMEDCT_US |
D008713 | MESH_DESCRIPTOR_UI |
4198 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0205 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-0210 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-070 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-070 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-071 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-071 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-008 | TABLET | 5 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42254-009 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-640 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-640 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-641 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49884-641 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2366 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3334 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51293-820 | TABLET | 5 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51293-821 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0850 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-0949 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
METHIMAZOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53808-1044 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5135 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6071 | TABLET | 5 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-380 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-381 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-357 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-370 | TABLET | 10 mg | ORAL | ANDA | 19 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-205 | TABLET | 5 mg | ORAL | ANDA | 12 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-206 | TABLET | 10 mg | ORAL | ANDA | 12 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2026 | TABLET | 5 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2027 | TABLET | 10 mg | ORAL | ANDA | 18 sections |
Methimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2224 | TABLET | 10 mg | ORAL | ANDA | 19 sections |